Therapeutics development for Anxiety Disorder Pipeline Review H2 2016 Anxiety Disorders - Pipeline Review, H2 2016

Anxiety Disorders Pipeline Review H2 2016
Global Markets Direct's, Anxiety Disorders- Pipeline Review, H2 2016', provides an
overview of the Anxiety Disorderspipeline landscape.
The report provides comprehensive information on the therapeutics under development for
Anxiety Disorders , complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research and development
history and latest news and press releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Anxiety Disorders and features dormant and
discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Complete report on Anxiety Disorders- Pipeline Review, H2 2016 addition with 88 market data
tables and 15 figures, spread across 273 pages http://www.rnrmarketresearch.com/anxietydisorders-pipeline-review-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas
and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug profiles featured in
the report undergoes periodic review following a stringent set of processes to ensure that all
the profiles are updated with the latest set of information. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a real time basis

Drugs Profile Discussed in this Research:
18-MC,acamprosate calcium SR,ACH-36,ADN-2013,ADX-71441,ADX-71743,ADX-88178,
alprazolam,AVN-0189,AM-3506,AVN-101,AVN-628,BNC-210,brexpiprazole,CPP-115,D-473,Drugs to
Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders,E-2508,evenamide, fluvoxamine
maleate ganaxolone , GT-001, IC-87201, INT-0036,INV-107,ITI-007,KDAC-0001,ketamine
hydrochloride lorazepam,lorazepam ER,modafinil,nabiximols,OMS-527,remeglurant, Rycal

Companies Discussed/Mentioned in this Research:
AbbVie , Ache Laboratorios Farmaceuticos, Adamed Sp., Amorsa Therapeutics, Addex Therapeutics,
Avineuro Pharmaceuticals, Azevan Pharmaceuticals, Biohaven Pharmaceutical Holding Company,
Bionomics Limited,Boehringer Ingelheim GmbH,CX Discovery Holdings PLC,Catalyst
Pharmaceuticals,Inc.,Corcept Therapeutics Incorporated,Edgemont Pharmaceuticals,LLC,Eisai
Co.Ltd.,Eli Lilly and Company,Fabre-Kramer Pharmaceuticals,Inc.,Gabather AB, GlaxoSmithKline
Plc,GW Pharmaceuticals Plc,Humanetics Corporation,IntelGenx Corp.,Intra-Cellular
Therapies,Inc.,INVENT Pharmaceuticals,Inc.,Lead Discovery Center GmbH,Marinus
Pharmaceuticals,Inc.,Merz Pharma GmbH & Co.KgaA,Neuralstem,Inc.,
Neurelis,Inc.,NeuroNascent,Inc.,Newron Pharmaceuticals S.p.A.,Nippon Chemiphar Co.Ltd.,Omeros

Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquirebefore-buying?rname=708046(This is a premium report price at US$2000 for a single user PDF
license).